Optimizing treatment of seminoma stage IIA/B step by step.

1. Rahma OE, Duffy A, Liewehr DJ et al. Second-line treatment in advanced pancreatic cancer: a comprehensive analysis of published clinical trials. Ann Oncol 2013. 2. Teo M, McDermott RS. Activity and survival benefit of second-line chemotherapy (2L-Ctx) in advanced pancreatic adenocarcinoma (APC): pooled analysis of the literature. J Clin Oncol 2013; (suppl: abstr e15019) 2013. 3. Collisson EA, Sadanandam A, Olson P et al. Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy. Nat Med 2011; 17: 500–503. 4. Boeck S, Heinemann V. Second-line therapy in gemcitabine-pretreated patients with advanced pancreatic cancer. J Clin Oncol 2008; 26: 1178–1179; author reply 9. 5. Grothey A, Sargent D. Overall survival of patients with advanced colorectal cancer correlates with availability of fluorouracil, irinotecan, and oxaliplatin regardless of whether doublet or single-agent therapy is used first line. J Clin Oncol 2005; 23: 9441–9442.